Castle Biosciences (CSTL) Total Non-Current Liabilities (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Total Non-Current Liabilities data on file, last reported at $84.9 million in Q1 2026.

• Quarterly Total Non-Current Liabilities changed N/A year-over-year to $84.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $84.9 million (changed N/A YoY) and the FY2025 annual result came in at $106.2 million, up 40.83% from the prior year.
• Total Non-Current Liabilities fell to $84.9 million in Q1 2026 per CSTL's latest filing, from $106.2 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $106.2 million in Q4 2025, with the low at $36.6 million in Q2 2022.
• Average Total Non-Current Liabilities over 5 years is $63.1 million, with a median of $53.1 million recorded in 2023.
• Year-over-year, Total Non-Current Liabilities jumped 151.53% in 2022 and fell 11.28% in 2023.
• Castle Biosciences' Total Non-Current Liabilities stood at $48.1 million in 2022, then climbed by 29.02% to $62.0 million in 2023, then advanced by 21.52% to $75.4 million in 2024, then surged by 40.83% to $106.2 million in 2025, then retreated by 20.05% to $84.9 million in 2026.
• Business Quant data shows CSTL's Total Non-Current Liabilities at $84.9 million in Q1 2026, $106.2 million in Q4 2025, and $94.2 million in Q3 2025.